Picture of Hikma Pharmaceuticals logo

HIK Hikma Pharmaceuticals News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareBalancedLarge CapNeutral

REG - Hikma Pharmaceutical - Annual Financial Report and Notice of AGM

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240322:nRSV9694Ha&default-theme=true

RNS Number : 9694H  Hikma Pharmaceuticals Plc  22 March 2024

Hikma Pharmaceuticals PLC

2023 Annual Report and Accounts and Notice of 2024 Annual General Meeting

 

LONDON, 22 March 2024: Hikma Pharmaceuticals PLC (the "Company") announces
that, the Annual Report and Accounts for the year ended 31 December 2023 (the
"Annual Report") and the Notice of the 2024 Annual General Meeting (the
"Notice of AGM") are today being made available to shareholders.

The Annual Report and Notice of AGM can be viewed or downloaded from the
Company's website at www.hikma.com/investors/2023-annual-report/
(http://www.hikma.com/investors/2023-annual-report/) .

In accordance with Listing Rule 9.6.1 copies of the Annual Report and Notice
of AGM have been submitted to the National Storage Mechanism and will shortly
be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

 

ENDS -

 

 

 

 

Enquiries

Hikma Pharmaceuticals PLC

 

Helen
Middlemist
+44 20 7399 2760

Group Company Secretary

22 March 2024

 

 

 

 

About Hikma

Hikma helps put better health within reach every day for millions of people
around the world. For more than 45 years, we've been creating high-quality
medicines and making them accessible to the people who need them.
Headquartered in the UK, we are a global company with a local presence across
North America, the Middle East and North Africa (MENA) and Europe, and we use
our unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed to our
customers, and the people they care for, and by thinking creatively and acting
practically, we provide them with a broad range of branded and non-branded
generic medicines. Together, our 9,100 colleagues are helping to shape a
healthier world that enriches all our communities. We are a leading licensing
partner, and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more information, please
visit: www.hikma.com (http://www.hikma.com) .

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY)
(LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P, BBB-/positive Fitch)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSUUUKRSRUOURR

Recent news on Hikma Pharmaceuticals

See all news